These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30218501)

  • 1. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders.
    Damato V; Balint B; Kienzler AK; Irani SR
    Mov Disord; 2018 Sep; 33(9):1376-1389. PubMed ID: 30218501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune movement disorders.
    Mckeon A; Vincent A
    Handb Clin Neurol; 2016; 133():301-15. PubMed ID: 27112684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody-associated movement disorders.
    Mohammad SS; Ramanathan S; Brilot F; Dale RC
    Neuropediatrics; 2013 Dec; 44(6):336-45. PubMed ID: 24203856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.
    Balint B; Vincent A; Meinck HM; Irani SR; Bhatia KP
    Brain; 2018 Jan; 141(1):13-36. PubMed ID: 29053777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis.
    Ramanathan S; Al-Diwani A; Waters P; Irani SR
    J Neurol; 2021 May; 268(5):1689-1707. PubMed ID: 31655889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune encephalitis: clinical spectrum and management.
    Uy CE; Binks S; Irani SR
    Pract Neurol; 2021 Oct; 21(5):412-423. PubMed ID: 34108243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune Movement Disorders: a Clinical and Laboratory Approach.
    Honorat JA; McKeon A
    Curr Neurol Neurosci Rep; 2017 Jan; 17(1):4. PubMed ID: 28120141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody-mediated diseases of the CNS: Structure, dysfunction and therapy.
    Varley J; Taylor J; Irani SR
    Neuropharmacology; 2018 Apr; 132():71-82. PubMed ID: 28476644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies.
    McGinty RN; Handel A; Moloney T; Ramesh A; Fower A; Torzillo E; Kramer H; Howell S; Waters P; Adcock J; Sen A; Lang B; Irani SR
    J Neurol Neurosurg Psychiatry; 2021 Mar; 92(3):291-294. PubMed ID: 33219046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibody-Associated Movement Disorders in Children: Proven and Proposed.
    Singer HS
    Semin Pediatr Neurol; 2017 Aug; 24(3):168-179. PubMed ID: 29103424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry.
    Sinmaz N; Amatoury M; Merheb V; Ramanathan S; Dale RC; Brilot F
    Ann N Y Acad Sci; 2015 Sep; 1351():22-38. PubMed ID: 26083906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Movement Disorders.
    Fearon C; O'Toole O
    Semin Neurol; 2018 Jun; 38(3):316-329. PubMed ID: 30011412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-associated epilepsies: Clinical features, evidence for immunotherapies and future research questions.
    Bakpa OD; Reuber M; Irani SR
    Seizure; 2016 Oct; 41():26-41. PubMed ID: 27450643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Movement disorders associated with neuronal antibodies.
    Dash D; Pandey S
    Acta Neurol Scand; 2019 Feb; 139(2):106-117. PubMed ID: 30338517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders.
    Sinmaz N; Tea F; Pilli D; Zou A; Amatoury M; Nguyen T; Merheb V; Ramanathan S; Cooper ST; Dale RC; Brilot F
    Acta Neuropathol Commun; 2016 Dec; 4(1):126. PubMed ID: 27908295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody-Associated Central Nervous System Neurologic Disorders.
    Linnoila J; Pittock SJ
    Semin Neurol; 2016 Aug; 36(4):382-96. PubMed ID: 27643908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome.
    Pillai SC; Hacohen Y; Tantsis E; Prelog K; Merheb V; Kesson A; Barnes E; Gill D; Webster R; Menezes M; Ardern-Holmes S; Gupta S; Procopis P; Troedson C; Antony J; Ouvrier RA; Polfrit Y; Davies NW; Waters P; Lang B; Lim MJ; Brilot F; Vincent A; Dale RC
    Pediatrics; 2015 Apr; 135(4):e974-84. PubMed ID: 25802349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles and approaches to the treatment of immune-mediated movement disorders.
    Mohammad SS; Dale RC
    Eur J Paediatr Neurol; 2018 Mar; 22(2):292-300. PubMed ID: 29289523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunology underlying CNS autoantibody diseases.
    Cleaver J; Ceronie B; Strippel C; Handel A; Irani SR
    Rev Neurol (Paris); 2024 Nov; 180(9):916-930. PubMed ID: 39289136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    Abboud H; Rossman I; Mealy MA; Hill E; Thompson N; Banerjee A; Probasco J; Levy M
    J Neurol; 2017 Nov; 264(11):2284-2292. PubMed ID: 28975404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.